Serozni karcinom jajnika niskog gradusa

master's thesis

• Title (english): Low grade serous ovarian cancer
• Author: Karlo Grudić
• Mentor: Joško Lešin (mentor)
• Committee member: Goran Vujić (predsjednik povjerenstva)
• Committee member: Dinka Pavičić Baldani (član povjerenstva)
• Committee member: Joško Lešin (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Gynecology and Obstetrics); Zagreb
• Defense date and country: 2022-07-15, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Gynecology and Obstetrics

Abstract

Serozni kacinom jajnika niskog gradusa je podvrsta karcinoma ovarija kojeg karakterizira manje agresivno ponašanje i bolji klinički ishod od drugih karcinoma ovarija. Bolest se najčešće dijagnosticira ultrazvučno, CT-om ili MR-om. Relativno je kemorezistentan i zbog toga je citoreduktivna operacija zlatni standard u ranim stadijima bolesti. Pacijentice sa višim stadijima bolesti nakon primarne operacije primaju adjuvantnu terapiju. Neoadjuvantna kemoterapija se koristi kod uznapredovale bolesti u kojoj zbog stanja pacijentice operacija nije moguća. Za održavanje remisije se u terapiji primjenjuje se i hormonska terapija i ciljana terapija poput anti-VEGF protutijela bevacizumab. U ovom istraživanju pomoću baze podataka istražujemo ishode liječenja, OS i PFS kod primjene raznih modaliteta kemoterapije i operativnog liječenja i njihov utjecaj na konačnu prognozu kod pacijentica.

Abstract (english)

Low-grade serous ovarian cancer is a subtype of ovarian cancer characterized by less aggressive behaviour and a better clinical outcome than other ovarian cancers. The disease is most commonly diagnosed by ultrasound, CT, or MR. It is relatively chemoresistant and therefore cytoreductive surgery is the gold standard in the early stages of the disease. Patients with higher stages of the disease receive adjuvant therapy after primary surgery. Neoadjuvant chemotherapy is used in advanced disease in which surgery is not possible due to the patient's condition. To maintain remission, both hormone therapy and targeted therapy such as the anti-VEGF antibody bevacizumab are used in therapy. In this study, we use a database to investigate treatment outcomes, OS and PFS in the application of various modalities of chemotherapy and surgical treatment and their impact on the final prognosis in patients.

• Keywords: Kirurški zahvati citoredukcije; Bevacizumab; Neoadjuvantna terapija; Serozni cistadenokarcinom; Neoplazme jajnika
• Keywords (english): Kirurški zahvati citoredukcije; Bevacizumab; Neoadjuvantna terapija; Serozni cistadenokarcinom; Neoplazme jajnika
• Language: croatian
• URN:NBN: urn:nbn:hr:105:548689
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2023-01-09 10:02:45